BRPI0707480A8 - Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos - Google Patents

Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos

Info

Publication number
BRPI0707480A8
BRPI0707480A8 BRPI0707480A BRPI0707480A BRPI0707480A8 BR PI0707480 A8 BRPI0707480 A8 BR PI0707480A8 BR PI0707480 A BRPI0707480 A BR PI0707480A BR PI0707480 A BRPI0707480 A BR PI0707480A BR PI0707480 A8 BRPI0707480 A8 BR PI0707480A8
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
antibody
nucleotide sequence
vector
product
Prior art date
Application number
BRPI0707480A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Comoglio Paolo
Original Assignee
Vertical Bio Ag
Metheresis Translational Res S A
Metis Prec Medicine Sb S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertical Bio Ag, Metheresis Translational Res S A, Metis Prec Medicine Sb S R L filed Critical Vertical Bio Ag
Publication of BRPI0707480A2 publication Critical patent/BRPI0707480A2/pt
Publication of BRPI0707480A8 publication Critical patent/BRPI0707480A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0707480A 2006-02-06 2007-02-05 Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos BRPI0707480A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06101345.4 2006-02-06
EP06101345 2006-02-06
PCT/EP2007/051066 WO2007090807A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Publications (2)

Publication Number Publication Date
BRPI0707480A2 BRPI0707480A2 (pt) 2011-05-03
BRPI0707480A8 true BRPI0707480A8 (pt) 2022-11-08

Family

ID=36616994

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707480A BRPI0707480A8 (pt) 2006-02-06 2007-02-05 Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos

Country Status (21)

Country Link
US (2) US8388958B2 (OSRAM)
EP (2) EP2192188A1 (OSRAM)
JP (1) JP5306828B2 (OSRAM)
KR (1) KR101429297B1 (OSRAM)
CN (1) CN101379192B (OSRAM)
AT (1) ATE514715T1 (OSRAM)
AU (1) AU2007213804B2 (OSRAM)
BR (1) BRPI0707480A8 (OSRAM)
CA (1) CA2638889C (OSRAM)
CY (1) CY1111884T1 (OSRAM)
DK (1) DK1981981T3 (OSRAM)
EA (1) EA015580B1 (OSRAM)
ES (1) ES2368864T3 (OSRAM)
IL (1) IL192879A (OSRAM)
MX (1) MX2008009833A (OSRAM)
PL (1) PL1981981T3 (OSRAM)
PT (1) PT1981981E (OSRAM)
SG (2) SG169382A1 (OSRAM)
SI (1) SI1981981T1 (OSRAM)
WO (1) WO2007090807A1 (OSRAM)
ZA (1) ZA200806559B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) * 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
WO2011125458A1 (ja) 2010-04-02 2011-10-13 富士レビオ株式会社 抗癌剤の効果の診断用マーカー
EP2808344A1 (en) * 2010-06-01 2014-12-03 Monash University Antibodies directed to the receptor tyrosine kinase c-Met
RU2013114783A (ru) * 2010-09-03 2014-10-10 Академиа Синика Anti-с-мет антитела и способы их применения
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
ES2489475T3 (es) * 2011-03-18 2014-09-02 Metheresis Translational Research Sa Inhibidores MET para potenciar la eficacia de la radioterapia
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
WO2013079973A1 (en) 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
EP2863946A4 (en) * 2012-06-21 2016-04-13 Sorrento Therapeutics Inc ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
KR102200274B1 (ko) 2014-09-16 2021-01-08 심포젠 에이/에스 항-ｍｅｔ 항체 및 조성물
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
JP6942179B2 (ja) * 2016-09-29 2021-09-29 田辺三菱製薬株式会社 ｃＭＥＴモノクローナル結合剤、その薬物複合体およびその使用
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
WO2019189453A1 (en) 2018-03-28 2019-10-03 Mitsubishi Tanabe Pharma Corporation DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2024246356A1 (en) 2023-06-01 2024-12-05 Pierre Fabre Medicament Silenced antibody-based anti-met constructs for the treatment of tumors and metastasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
AU2007213804A8 (en) 2008-08-28
EA200870234A1 (ru) 2009-02-27
IL192879A (en) 2014-02-27
CA2638889A1 (en) 2007-08-16
EP1981981A1 (en) 2008-10-22
EP1981981B1 (en) 2011-06-29
CN101379192A (zh) 2009-03-04
WO2007090807A1 (en) 2007-08-16
US8388958B2 (en) 2013-03-05
JP5306828B2 (ja) 2013-10-02
SG169383A1 (en) 2011-03-30
US20090285807A1 (en) 2009-11-19
ES2368864T3 (es) 2011-11-23
PT1981981E (pt) 2011-10-04
CN101379192B (zh) 2013-07-31
EA015580B1 (ru) 2011-10-31
SI1981981T1 (sl) 2012-01-31
PL1981981T3 (pl) 2011-11-30
KR20090013745A (ko) 2009-02-05
US20120134996A1 (en) 2012-05-31
ZA200806559B (en) 2012-12-27
CA2638889C (en) 2015-06-02
MX2008009833A (es) 2008-10-23
AU2007213804A1 (en) 2007-08-16
SG169382A1 (en) 2011-03-30
EP2192188A1 (en) 2010-06-02
DK1981981T3 (da) 2011-09-26
ATE514715T1 (de) 2011-07-15
AU2007213804B2 (en) 2012-12-13
US8729043B2 (en) 2014-05-20
IL192879A0 (en) 2009-02-11
CY1111884T1 (el) 2015-11-04
JP2009526010A (ja) 2009-07-16
KR101429297B1 (ko) 2014-08-12
BRPI0707480A2 (pt) 2011-05-03

Similar Documents

Publication Publication Date Title
BRPI0707480A8 (pt) Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos
CY1123936T1 (el) Μεθοδος παρασκευης παραγωγών οξαζολο[4,5-β]πυριδινης και θειαζολο[4,5-β]πυριδινης ως αναστολεων irak4 για την αγωγη του καρκινου
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
EP2041274A4 (en) PREPARATION OF A SHORT-COATED VOLATILE HYDROCARBON BASED ON GENERALLY MANIPULATED MICROALGEN, CYANOBACTERIA OR BACTERIA
EA200970738A1 (ru) Ингибиторы активности akt
NO20092725L (no) Quinazoliner for PDK1 inhibering
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
NZ603478A (en) 2 -aminopyridine derivatives useful as inhibitors of atr kinase
BR112012010085A2 (pt) inibidores de quinases
EP2181081A4 (en) METHOD FOR OLIGOMERIZING OLEFINES
NZ607337A (en) Antibodies for epidermal growth factor receptor 3 (her3)
EA201170872A1 (ru) Ингибиторы протеинкиназы
CY1114277T1 (el) ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
BRPI0715580A2 (pt) ''ANTICORPO ANTI-LINFOTOXINA-a (LTa) ISOLADO, ANTICORPO HUMANIZADO, ANTICORPOS ANTI-LINFOTOXINA-a,COMPOSIÇÃO DE ANTICORPO,ANTICORPO ANTI-IDIOTIPO,HIBRIDOMA,ANTICORPO,ÁCIDO NUCLÉICO ISOLADO, VETOR DE EXPRESSÃO,CÉLULA HOSPEDEIRA,MÉTODO DE PRODUÇÃO DE UM ANTICORPO,MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR ATIVADA POR LTa, MÉTODO PARA TRATAR UM DISTURBIO AUTO-IMUNE, ARTIGOS MANUFATURADOS, MÉTODO PARA DIVULGAR UM ANTICORPO E MÉTODO PARA EMBALAR O ANTICORPO''
ATE527253T1 (de) Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
BRPI0518794A2 (pt) composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial
WO2010149578A3 (en) Novel biphenyl and phenyl-pyridine amides
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: METIS PRECISION MEDICINE SB S.R.L. (IT)

B25A Requested transfer of rights approved

Owner name: VERTICAL BIO AG (CH)